Evidence map›Paper›PMID 41179750›Full record

ArticleFrontiers in public health2025

Getting ahead of the ageing curve: learning from EU experiences for a healthier demographic transition.

Hércules Rezende Freitas, João Oliveira Malva

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hércules Rezende FreitasDepartment of Integrated Medical Sciences, School of Medicine, Rio de Janeiro State University, Rio de Janeiro, Brazil.
João Oliveira MalvaCoimbra Institute for Clinical and Biomedical Research (iCBR) CIBB - Center for Innovative Biomedicine and Biotechnology and Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Population ageing is accelerating worldwide, with one in six people projected to be over 60 by 2030. This demographic shift is already evident in Europe, with slower life-expectancy gains, widening healthspan-lifespan gaps, and growing labour shortages. In this paper, we examine global projections, country-level disparities, evidence from economics, geroscience and public health to assess the conditions under which longevity can generate a net social dividend. Our analysis highlights recent advances in ageing research, including stem-cell, epigenetic and anti-inflammatory interventions, as well as meta-research efforts to promote community-driven consensus on strategic geroscience problems. Translating these insights into societal benefits require regulatory recognition of ageing as a treatable condition, equitable access to innovation, and living-lab ecosystems that connect bench discoveries to health and social care. Using fiscal modelling, we show that disability-driven expenditure could rise by as much as 2.7% of EU GDP annually by 2070, unless offset by slower biological ageing or managed migration. Finally, we suggest that European experiences, particularly from the Iberian Peninsula, can inform South American countries now entering rapid demographic transition.

Indexed as

AgingLife ExpectancyPopulation DynamicsAgedEuropeEuropean UnionHumansMiddle AgedPublic Healthdemographic transitiongerosciencehealthspan–lifespan gaphealthy longevitypolicy integration

Identifiers

PMID41179750
PMCPMC12575190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.